Swift to use Horizon NGS reference standards
Swift Biosciences will incorporate Horizon Discovery Group‘s human genomic reference standards into its new Accel-Amplicon 56G Oncology Panel for use in research and translational applications.
Swift will include Horizon’s HDx Quantitative Multiplex Reference Standard material as a positive control in its trial-size oncology panel, allowing users to validate the panel for use in next-gen applications in their lab. HDx Reference Standards offer a source of genetically defined, quantitative, sustainable, and independent third-party reference material, and are the first commercially available standards of their kind, Horizon said.
“Our ability to engineer cell lines with almost any genetic alteration required is increasingly attracting the attention of the diagnostics community,” Horizon president of products Paul Morrill said in a statement. “This agreement is further recognition of the importance of providing controls alongside a targeted sequencing assay, and we are very pleased to partner with Swift to help ensure the accuracy of their new assay.”